Orbital Signs of Parasellar Syndromes

Chapter

Abstract

Retro-orbital pathology involving the parasellar region can cause signs and symptoms that can be mistaken for orbital disease. Patients can present with a combination of proptosis, eyelid edema and erythema, chemosis, vision loss, numbness, and ophthalmoplegia with or without pain. A retro-orbital process should be considered when ophthalmoplegia is more consistent with a cranial neuropathy affecting the oculomotor nerve (CN 3), trochlear nerve (CN 4), or abducens nerve (CN 6) rather than extraocular muscle limitation. They have been divided anatomically into the superior orbital fissure syndrome (SOFS), orbital apex syndrome (OAS), or cavernous sinus syndrome (CSS).

Keywords

Lymphoma Neuropathy Streptomyces Vasculitis Encephalitis 

References

  1. 1.
    Tubbs RS, Hill M, May WR, et al. Does the maxillary division of the trigeminal nerve traverse the cavernous sinus? An anatomical study and review of the literature. Surg Radiol Anat. 2008;30:37–40.PubMedCrossRefGoogle Scholar
  2. 2.
    Fernández S, Godino O, Martínez-Yélamos S, Mesa E, Arruga J, Ramón JM, Acebes JJ, Rubio F. Cavernous sinus syndrome: a series of 126 patients. Medicine (Baltimore). 2007;86:278–81.CrossRefGoogle Scholar
  3. 3.
    Lin CC, Tsai JJ. Relationship between the number of involved cranial nerves and the percentage of lesions located in the cavernous sinus. Eur Neurol. 2003;49(2):98–102.PubMedCrossRefGoogle Scholar
  4. 4.
    Kline LB. The Tolosa-Hunt syndrome. Surv Ophthalmol. 1982;27:79–95.PubMedCrossRefGoogle Scholar
  5. 5.
    Thomas JE, Yoss RE. The parasellar syndrome: problems in determining etiology. Mayo Clin Proc. 1970;45:617–23.PubMedGoogle Scholar
  6. 6.
    Keane JR. Cavernous sinus syndrome. Analysis of 151 cases. Arch Neurol. 1996;53:967–71.PubMedCrossRefGoogle Scholar
  7. 7.
    Rush JA, Younge BR. Paralysis of cranial nerves III, IV, and VI. Cause and prognosis in 1,000 cases. Arch Ophthalmol. 1981;99:76–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Jefferson G. Concerning injuries, aneurysms and tumours involving the cavernous sinus. Trans Ophthalmol Soc U K. 1953;73:117–52.Google Scholar
  9. 9.
    Godtfredsen E, Lederman M. Diagnostic and prognostic roles of ophthalmoneurologic signs and symptoms in malignant nasopharyngeal tumors. Am J Ophthalmol. 1965;59:1063–9.PubMedGoogle Scholar
  10. 10.
    Sibal L, Ball SG, Connolly V, et al. Pituitary apoplexy: a review of clinical presentation, management and outcome in 45 cases. Pituitary. 2004;7:157–63.PubMedCrossRefGoogle Scholar
  11. 11.
    Kalina P, Black K, Woldenberg R. Burkitt’s lymphoma of the skull base presenting as cavernous sinus syndrome in early childhood. Pediatr Radiol. 1996;26:416–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Rubin MM, Sanfilippo RJ. Lymphoma of the paranasal sinuses presenting as cavernous sinus syndrome. J Oral Maxillofac Surg. 1992;50:749–51.PubMedCrossRefGoogle Scholar
  13. 13.
    Barrow DL, Spector RH, Braun IF, et al. Classification and treatment of spontaneous carotid-cavernous sinus fistulas. J Neurosurg. 1985;62:248–56.PubMedCrossRefGoogle Scholar
  14. 14.
    Preechawat P, Narmkerd P, Jiarakongmun P, et al. Dural carotid cavernous sinus fistula: ocular characteristics, endovascular management and clinical outcome. J Med Assoc Thai. 2008;91:852–8.PubMedGoogle Scholar
  15. 15.
    Oishi A, Miyamoto K, Yoshimura N. Etiology of carotid cavernous fistula in Japanese. Jpn J Ophthalmol. 2009;53:40–3.PubMedCrossRefGoogle Scholar
  16. 16.
    Debrun GM, Viñuela F, Fox AJ, et al. Indications for treatment and classification of 132 carotid-cavernous fistulas. Neurosurgery. 1988;22:285–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Kirsch M, Henkes H, Liebig T, et al. Endovascular management of dural carotid-cavernous sinus fistulas in 141 patients. Neuroradiology. 2006;48:486–90.PubMedCrossRefGoogle Scholar
  18. 18.
    Meyers PM, Halbach VV, Dowd CF, et al. Dural carotid cavernous fistula: definitive endovascular management and long-term follow-up. Am J Ophthalmol. 2002;134:85–92.PubMedCrossRefGoogle Scholar
  19. 19.
    Leonard TJ, Moseley IF, Sanders MD. Ophthalmoplegia in carotid cavernous sinus fistula. Br J Ophthalmol. 1984;68:128–34.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Chen CC, Chang PC, Shy CG, et al. CT angiography and MR angiography in the evaluation of carotid cavernous sinus fistula prior to embolization: a comparison of techniques. AJNR Am J Neuroradiol. 2005;26:2349–56.PubMedGoogle Scholar
  21. 21.
    Halbach VV, Hieshima GB, Higashida RT, et al. Carotid cavernous fistulae: indications for urgent treatment. AJR Am J Roentgenol. 1987;149:587–93.PubMedCrossRefGoogle Scholar
  22. 22.
    Halbach VV, Higashida RT, Hieshima GB, et al. Dural fistulas involving the cavernous sinus: results of treatment in 30 patients. Radiology. 1987;163:437–42.PubMedGoogle Scholar
  23. 23.
    Higashida RT, Hieshima GB, Halbach VV, et al. Closure of carotid cavernous sinus fistulae by external compression of the carotid artery and jugular vein. Acta Radiol Suppl. 1986;369:580–3.PubMedGoogle Scholar
  24. 24.
    Serbinenko FA. Balloon catheterization and occlusion of major cerebral vessels. J Neurosurg. 1974;41:125–45.PubMedCrossRefGoogle Scholar
  25. 25.
    Lewis AI, Tomsick TA, Tew Jr JM, et al. Long-term results in direct carotid-cavernous fistulas after treatment with detachable balloons. J Neurosurg. 1996;84:400–4.PubMedCrossRefGoogle Scholar
  26. 26.
    Debrun G, Lacour P, Vinuela F, et al. Treatment of 54 traumatic carotid-cavernous fistulas. J Neurosurg. 1981;55:678–92.PubMedCrossRefGoogle Scholar
  27. 27.
    Goldberg RA, Goldey SH, Duckwiler G, et al. Management of cavernous sinus-dural fistulas. Indications and techniques for primary embolization via the superior ophthalmic vein. Arch Ophthalmol. 1996;114:707–14.PubMedCrossRefGoogle Scholar
  28. 28.
    Keltner JL, Satterfield D, Dublin AB, et al. Dural and carotid cavernous sinus fistulas. Diagnosis, management, and complications. Ophthalmology. 1987;94:1585–600.PubMedCrossRefGoogle Scholar
  29. 29.
    Yoshida K, Melake M, Oishi H, et al. Transvenous embolization of dural carotid cavernous fistulas: a series of 44 consecutive patients. AJNR Am J Neuroradiol. 2010;31:651–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Morón FE, Klucznik RP, Mawad ME, et al. Endovascular treatment of high-flow carotid cavernous fistulas by stent-assisted coil placement. AJNR Am J Neuroradiol. 2005;26:1399–404.PubMedGoogle Scholar
  31. 31.
    Archondakis E, Pero G, Valvassori L, et al. Angiographic follow-up of traumatic carotid cavernous fistulas treated with endovascular stent graft placement. AJNR Am J Neuroradiol. 2007;28:342–7.PubMedGoogle Scholar
  32. 32.
    Wang C, Xie X, You C, et al. Placement of covered stents for the treatment of direct carotid cavernous fistulas. AJNR Am J Neuroradiol. 2009;30:1342–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Linskey ME, Sekhar LN, Hirsch Jr W, et al. Aneurysms of the intracavernous carotid artery: clinical presentation, radiographic features, and pathogenesis. Neurosurgery. 1990;26:71–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Kannoth S, Iyer R, Thomas SV, Furtado SV, Rajesh BJ, Kesavadas C, Radhakrishnan VV, Sarma PS. Intracranial infectious aneurysm: presentation, management and outcome. J Neurol Sci. 2007;256:3–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Wiebers DO, Whisnant JP, Huston 3rd J, For the International Study of Unruptured Intracranial Aneurysms Investigators, et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet. 2003;362:103–10.PubMedCrossRefGoogle Scholar
  36. 36.
    Kupersmith MJ, Stiebel-Kalish H, Huna-Baron R, et al. Cavernous carotid aneurysms rarely cause subarachnoid hemorrhage or major neurologic morbidity. J Stroke Cerebrovasc Dis. 2002;11:9–14.PubMedCrossRefGoogle Scholar
  37. 37.
    Linskey ME, Sekhar LN, Hirsch Jr WL, et al. Aneurysms of the intracavernous carotid artery: natural history and indications for treatment. Neurosurgery. 1990;26:933–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Tolosa E. Periarteritic lesions of the carotid siphon with the clinical features of a carotid infraclinoidal aneurysm. J Neurol Neurosurg Psychiatry. 1954;17:300–2.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Hunt WE, Meagher JN, Lefever HE, et al. Painful opthalmoplegia. Its relation to indolent inflammation of the carvernous sinus. Neurology. 1961;11:56–62.PubMedCrossRefGoogle Scholar
  40. 40.
    Smith JL, Taxdal DS. Painful ophthalmoplegia. The Tolosa-Hunt syndrome. Am J Ophthalmol. 1966;61:1466–72.PubMedGoogle Scholar
  41. 41.
    The International Classification of headache disorders. ICHD-II. Cephalalgia. 2004;24:131.Google Scholar
  42. 42.
    Hannerz J. Pain characteristics of painful ophthalmoplegia (the Tolosa-Hunt syndrome). Cephalalgia. 1985;5:103–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Gonzales GR. Pain in Tolosa-Hunt syndrome. J Pain Symptom Manage. 1998;16:199–204.PubMedCrossRefGoogle Scholar
  44. 44.
    La Mantia L, Curone M, Rapoport AM, Bussone G. Tolosa-Hunt syndrome: critical literature review based on IHS 2004 criteria. International Headache Society. Cephalalgia. 2006;26(7):772–81.PubMedCrossRefGoogle Scholar
  45. 45.
    Colnaghi S, Versino M, Marchioni E, et al. ICHD-II diagnostic criteria for Tolosa-Hunt syndrome in idiopathic inflammatory syndromes of the orbit and/or the cavernous sinus. Cephalalgia. 2008;28:577–84.PubMedCrossRefGoogle Scholar
  46. 46.
    de Arcaya AA, Cerezal L, Canga A, et al. Neuroimaging diagnosis of Tolosa-Hunt syndrome: MRI contribution. Headache. 1999;39:321–5.PubMedCrossRefGoogle Scholar
  47. 47.
    Muhletaler CA, Gerlock Jr AJ. Orbital venography in painful ophthalmoplegia (Tolosa-Hunt syndrome). AJR Am J Roentgenol. 1979;133:31–4.PubMedCrossRefGoogle Scholar
  48. 48.
    Goto Y, Goto I, Hosokawa S. Neurological and radiological studies in painful ophthalmoplegia: Tolosa-Hunt syndrome and orbital pseudotumour. J Neurol. 1989;236:448–51.PubMedCrossRefGoogle Scholar
  49. 49.
    Curone M, Tullo V, Proietti-Cecchini A, et al. Painful ophthalmoplegia: a retrospective study of 23 cases. Neurol Sci. 2009;30:S133–1355.PubMedCrossRefGoogle Scholar
  50. 50.
    Haque TL, Miki Y, Kashii S, et al. Dynamic MR imaging in Tolosa-Hunt syndrome. Eur J Radiol. 2004;51:209–17.PubMedCrossRefGoogle Scholar
  51. 51.
    Hannerz J, Ericson K, Bergstrand G. A new etiology for visual impairment and chronic headache. The Tolosa-Hunt syndrome may be only one manifestation of venous vasculitis. Cephalalgia. 1986;6:59–63.PubMedCrossRefGoogle Scholar
  52. 52.
    Foubert-Samier A, Sibon I, Maire JP, et al. Long-term cure of Tolosa-Hunt syndrome after low-dose focal radiotherapy. Headache. 2005;45:389–91.PubMedCrossRefGoogle Scholar
  53. 53.
    Mormont E, Laloux P, Vauthier J, et al. Radiotherapy in a case of Tolosa-Hunt syndrome. Cephalalgia. 2000;20:931–3.PubMedCrossRefGoogle Scholar
  54. 54.
    Furukawa Y, Yamaguchi W, Ito K, et al. The efficacy of radiation monotherapy for Tolosa-Hunt syndrome. J Neurol. 2010;257:288–90.PubMedCrossRefGoogle Scholar
  55. 55.
    Hatton MP, Rubin PA, Foster CS. Successful treatment of idiopathic orbital inflammation with mycophenolate mofetil. Am J Ophthalmol. 2005;140:916–8.PubMedCrossRefGoogle Scholar
  56. 56.
    O’ Connor G, Hutchinson M. Tolosa-Hunt syndrome responsive to infliximab therapy. J Neurol. 2009;256:660–1.PubMedCrossRefGoogle Scholar
  57. 57.
    Schafranski MD. Idiopathic orbital inflammatory disease successfully treated with rituximab. Clin Rheumatol. 2009;28:225–6.PubMedCrossRefGoogle Scholar
  58. 58.
    Smith JR, Rosenbaum JT. A role for methotrexate in the management of non-infectious orbital inflammatory disease. Br J Ophthalmol. 2001;85:1220–4.PubMedCentralPubMedCrossRefGoogle Scholar
  59. 59.
    Förderreuther S, Straube A. The criteria of the International Headache Society for Tolosa-Hunt syndrome need to be revised. J Neurol. 1999;246:371–7.PubMedCrossRefGoogle Scholar
  60. 60.
    Grove WE. Septic and aseptic types of thrombosis of the cavernous sinus. Arch Otolaryngol. 1936;24:29–50.CrossRefGoogle Scholar
  61. 61.
    Yarington CT. The prognosis and treatment of cavernous sinus thrombosis. Review of 878 cases in the literature. Ann Otol Rhinol Laryngol. 1961;70:263–7.PubMedGoogle Scholar
  62. 62.
    Levine SR, Twyman RE, Gilman S. The role of anticoagulation in cavernous sinus thrombosis. Neurology. 1988;38:517–22.PubMedCrossRefGoogle Scholar
  63. 63.
    Shaw RE. Cavernous sinus thrombophlebitis: a review. Br J Surg. 1952;40:40–8.PubMedCrossRefGoogle Scholar
  64. 64.
    Schuknecht B, Simmen D, Yüksel C, et al. Tributary venosinus occlusion and septic cavernous sinus thrombosis: CT and MR findings. AJNR Am J Neuroradiol. 1998;19:617–26.PubMedGoogle Scholar
  65. 65.
    Choe CH, Trobe JD. Morning rounds: the potentially fatal red eye. EyeNet. 2009;13(3):69–71.Google Scholar
  66. 66.
    Southwick FS, Richardson Jr EP, Swartz MN. Septic thrombosis of the dural venous sinuses. Medicine (Baltimore). 1986;65:82–106.CrossRefGoogle Scholar
  67. 67.
    Hargrove RN, Wesley RE, Klippenstein KA, et al. Indications for orbital exenteration in mucormycosis. Ophthal Plast Reconstr Surg. 2006;22:286–91.PubMedCrossRefGoogle Scholar
  68. 68.
    Peterson KL, Wang M, Canalis RF. Rhinocerebral mucormycosis: evolution of the disease and treatment options. Laryngoscope. 1997;107:855–62.PubMedCrossRefGoogle Scholar
  69. 69.
    Fleckner RA, Goldstein JH. Mucormycosis. Br J Ophthalmol. 1969;53:542–8.PubMedCentralPubMedCrossRefGoogle Scholar
  70. 70.
    Schwartz JN, Donnelly EH, Klintworth GK. Ocular and orbital phycomycosis. Surv Ophthalmol. 1977;22:3–28.PubMedCrossRefGoogle Scholar
  71. 71.
    Blitzer A, Lawson W, Meyers BR, et al. Patient survival factors in paranasal sinus mucormycosis. Laryngoscope. 1980;90:635–48.PubMedCrossRefGoogle Scholar
  72. 72.
    Yohai RA, Bullock JD, Aziz AA, et al. Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol. 1994;39:3–22.PubMedCrossRefGoogle Scholar
  73. 73.
    Ferry AP. Cerebral mucornlycosis (phycomycosis). Ocular tindings and review of tile literature. Surv Ophthalmol. 1961;6:1–24.PubMedGoogle Scholar
  74. 74.
    Ghadiali MT, Deckard NA, Farooq U, et al. Frozen-section biopsy analysis for acute invasive fungal rhinosinusitis. Otolaryngol Head Neck Surg. 2007;136:714–9.PubMedCrossRefGoogle Scholar
  75. 75.
    Hofman V, Castillo L, Bétis F, et al. Usefulness of frozen section in rhinocerebral mucormycosis diagnosis and management. Pathology. 2003;35:212–6.PubMedCrossRefGoogle Scholar
  76. 76.
    Langford JD, McCartney DL, Wang RC. Frozen section–guided surgical debridement for management of rhino-orbital mucormycosis. Am J Ophthalmol. 1997;124:265–7.PubMedGoogle Scholar
  77. 77.
    Songu M, Unlu HH, Gunhan K, et al. Orbital exenteration: a dilemma in mucormycosis presented with orbital apex syndrome. Am J Rhinol. 2008;22:98–103.PubMedCrossRefGoogle Scholar
  78. 78.
    Kahana A, Lucarelli MJ. Use of radiopaque intraorbital catheter in the treatment of sino-orbito-cranial mucormycosis. Arch Ophthalmol. 2007;125:1714–5.PubMedCrossRefGoogle Scholar
  79. 79.
    Price JC, Stevens DL. Hyperbaric oxygen in the treatment of rhinocerebral mucormycosis. Laryngoscope. 1980;90:737–47.PubMedCrossRefGoogle Scholar
  80. 80.
    Marsh RJ, Cooper M. Double-masked trial of topical acyclovir and steroids in the treatment of herpes zoster ocular inflammation. Br J Ophthalmol. 1991;75:542–6.PubMedCentralPubMedCrossRefGoogle Scholar
  81. 81.
    Cobo LM, Foulks GN, Liesegang T, et al. Oral acyclovir in the therapy of acute herpes zoster ophthalmicus. An interim report. Ophthalmology. 1985;92:1574–83.PubMedCrossRefGoogle Scholar
  82. 82.
    Whitley RJ, Weiss H, Gnann Jr JW, et al. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med. 1996;125:376–83.PubMedCrossRefGoogle Scholar
  83. 83.
    Wood MJ, Johnson RW, McKendrick MW, et al. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med. 1994;330:896–900.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of OphthalmologyUniversity of PennsylvaniaPhiladelphiaUSA
  2. 2.Department of Ophthalmology & Visual Sciences and NeurologyUniversity of MichiganAnn ArborUSA

Personalised recommendations